180 related articles for article (PubMed ID: 23752663)
21. Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.
Marcum ZA; Driessen J; Thorpe CT; Donohue JM; Gellad WF
Ann Pharmacother; 2015 Mar; 49(3):285-92. PubMed ID: 25515869
[TBL] [Abstract][Full Text] [Related]
22. Receipt of Overlapping Opioid and Benzodiazepine Prescriptions Among Veterans Dually Enrolled in Medicare Part D and the Department of Veterans Affairs: A Cross-sectional Study.
Carico R; Zhao X; Thorpe CT; Thorpe JM; Sileanu FE; Cashy JP; Hale JA; Mor MK; Radomski TR; Hausmann LRM; Donohue JM; Suda KJ; Stroupe K; Hanlon JT; Good CB; Fine MJ; Gellad WF
Ann Intern Med; 2018 Nov; 169(9):593-601. PubMed ID: 30304353
[TBL] [Abstract][Full Text] [Related]
23. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
24. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
[TBL] [Abstract][Full Text] [Related]
25. The role of county-level socioeconomic status on brand-name prescriptions in Medicare part D: A cross-sectional Study.
Volpi C; Shehadeh F; Mylonakis E
Medicine (Baltimore); 2020 Feb; 99(9):e19271. PubMed ID: 32118735
[TBL] [Abstract][Full Text] [Related]
26. Dual use of Department of Veterans Affairs and medicare benefits and use of test strips in veterans with type 2 diabetes mellitus.
Gellad WF; Zhao X; Thorpe CT; Mor MK; Good CB; Fine MJ
JAMA Intern Med; 2015 Jan; 175(1):26-34. PubMed ID: 25383920
[TBL] [Abstract][Full Text] [Related]
27. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
[TBL] [Abstract][Full Text] [Related]
28. Private expenditures on brand name prescription drugs after generic entry.
Balaban DY; Dhalla IA; Law MR; Bell CM
Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
[TBL] [Abstract][Full Text] [Related]
29. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Morse E; Hanna J; Mehra S
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387
[TBL] [Abstract][Full Text] [Related]
31. Opioid dispensing and overlap in veterans with non-cancer pain eligible for Medicare Part D.
Suda KJ; Smith BM; Bailey L; Gellad WF; Huo Z; Burk M; Cunningham F; Stroupe KT
J Am Pharm Assoc (2003); 2017; 57(3):333-340.e3. PubMed ID: 28408172
[TBL] [Abstract][Full Text] [Related]
32. Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure.
McGee BT; Phillips V; Higgins MK; Butler J
J Manag Care Spec Pharm; 2019 Jun; 25(6):705-713. PubMed ID: 31134861
[TBL] [Abstract][Full Text] [Related]
33. Should Medicare adopt the Veterans Health Administration formulary?
Frakt AB; Pizer SD; Feldman R
Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of dual drug benefit use among veterans with dementia enrolled in the Veterans Health Administration and Medicare Part D.
Schleiden LJ; Thorpe CT; Cashy JP; Gellad WF; Good CB; Hanlon JT; Mor MK; Niznik JD; Pleis JR; Van Houtven CH; Thorpe JM
Res Social Adm Pharm; 2019 Jun; 15(6):701-709. PubMed ID: 30236896
[TBL] [Abstract][Full Text] [Related]
35. Sending The Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less Than Generics?
Dusetzina SB; Jazowski S; Cole A; Nguyen J
Health Aff (Millwood); 2019 Jul; 38(7):1188-1194. PubMed ID: 31260351
[TBL] [Abstract][Full Text] [Related]
36. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.
Ross JS; Rohde S; Sangaralingham L; Brito JP; Choi L; Dutcher SK; Graham DJ; Jenkins MR; Lipska KJ; Mendoza M; Qiang Y; Wang Z; Wu Y; Yao X; Shah ND
J Clin Endocrinol Metab; 2019 Jun; 104(6):2305-2314. PubMed ID: 30690529
[TBL] [Abstract][Full Text] [Related]
37. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
38. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
39. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
40. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
